<unk>  is an selective estrogen receptor modulator that is FDA approved for the {{{indicationType}}} of osteoporosis in postmenopausal women, reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis, reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include hot flashes, leg cramps, peripheral edema, flu syndrome, arthralgia, sweating.
Raloxifene
Lasofoxifene
Ormeloxifene
Tamoxifen
Denosumab
Teriparatide
Enzalutamide
Zoledronic acid